More than 15 million Americans have coronary heart disease and most should be taking aspirin daily.1 Given aspirin’s ubiquity in cardiovascular medicine and patients’ pill boxes, it is shocking that there are still so many unanswered questions about aspirin use. Which dose and dosage forms should be prescribed? How common is aspirin resistance? What is the relationship between platelet inhibition and clinical outcomes?
The notion of aspirin “resistance” is... Read More
Many patients with atrial fibrillation (AF) received triple antithrombotic therapy after undergoing a percutaneous coronary intervention (PCI) and receiving cardiac stent. Triple therapy consists of warfarin plus dual antiplatelet therapy (DAPT) with a P2Y12 inhibitor and low-dose aspirin. But is triple therapy the best approach? This practice, while widely employed, is not entirely evidence-based. It’s actually the result of combining two evidence-based strategies – one to... Read More
My response to the question will be NO - Liraglutide based on the Leader trial cannot be added in the algorithm of DM-2 treatment as a second line agent next to Metformin. The logic is as follows:
Goal of DM-2 treatment is to lower the A1C value and BG level by adding another agent to the first line. Already the pt is at 8.1 or more. The LEADER trial discussed does not provide the outcome on these two parameters (not even the script providing the trail information), though the... Read More